Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.58 95% CI 0.45–0.76Authors' conclusion
In this real-world cohort of diabetic patients treated for colorectal cancer, GLP1-RA therapy was associated with a significant improvement in overall survival. These findings support the continued use of GLP1-RA agents in this population and may provide reassurance to clinicians and patients regarding the safety and potential benefit of these agents following a colorectal cancer diagnosis.
Study context
- Population
- Adults with T2D diagnosed with colorectal cancer between 2010 and 2025matched cohort
- Participants
- 751 vs 751
- Exposure
- GLP-1 RA use vs other oral antidiabetic drugs
- GLP1-RAn = 751
- non-GLP1-RAn = 751reference
- Outcome
- Overall survival
Methodological detailspropensity-score matched, TriNetX global health records network
- Propensity-score matched
- TriNetX global health records network
Main finding
All-cause mortality · median follow-up 731 days (GLP1-RA) and 779 days (non-GLP1-RA)
Hazard ratio
0.58
95% CI 0.45–0.76
P < 0.001
By group
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Metastasis-free survival (secondary outcome) · propensity score matched
HR for metastasis 0.60 (0.40–0.87) · P = 0.01
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| MACEDid not differ significantly | 0.84 (0.66–1.06) | P = 0.16 | |
| 0.512Hazard ratio (log scale) |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →